Other Hematological Diseases

Amyloidosis

HEMMYL0034
A Phase 2, Open-Label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients with AL Amyloidosis

PI: Liedtke
Pending

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
ImmunoTherapy
Enrollment on Hold